EGFR and glioblastoma: Importantly, compensatory mechanisms may vary across GBM subtypes—mesenchymal GBMs with NF-κB pathway activation may exhibit enhanced EGFR-independent resistance, while proneural subtypes may rely more on PDGFRA-mediated compensatory signaling [13].